Tumorigenicity studies for human pluripotent stem cell-derived products.
Human pluripotent stem cells (hPSCs), i.e. human embryonic stem cells and human induced pluripotent stem cells, are able to self-renew and differentiate into multiple cell types. Because of these abilities, numerous attempts have been made to utilize hPSCs in regenerative medicine/cell therapy. hPSCs are, however, also tumorigenic, that is, they can give rise to the progressive growth of tumor nodules in immunologically unresponsive animals. Therefore, assessing and managing the tumorigenicity of all final products is essential in order to prevent ectopic tissue formation, tumor development, and/or malignant transformation elicited by residual pluripotent stem cells after implantation. No detailed guideline for the tumorigenicity testing of hPSC-derived products has yet been issued for regenerative medicine/cell therapy, despite the urgent necessity. Here, we describe the current situations and issues related to the tumorigenicity testing of hPSC-derived products and we review the advantages and disadvantages of several types of tumorigenicity-associated tests. We also refer to important considerations in the execution and design of specific studies to monitor the tumorigenicity of hPSC-derived products.
Division of Cellular and Gene Therapy Products, National Institute of Health Sciences, 1–18–1 Kamiyoga, Setagaya-ku, Tokyo 158–8501, Japan.
Takuya
T
Kuroda
Satoshi
S
Yasuda
Yoji
Y
Sato
D000818:Animals; D002471:Cell Transformation, Neoplastic; D017408:Guidelines as Topic; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D039904:Pluripotent Stem Cells; D014944:World Health Organization